Sector News

Zymeworks could get up to $485M in expanded Daiichi I-O deal

May 15, 2018
Life sciences

When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps. Now, the pair is entering a new license agreement that could potentially be worth $484.7 million.

Under the original deal, Zymeworks licensed its Azymetric and Efect platforms to Daiichi Sankyo to develop a bispecific antibody therapy, for which Zymeworks is eligible to pick up milestone payments and royalties. It also received a license to certain immuno-oncology antibodies from Daiichi with the right to research, develop and market multiple bispecific products in exchange for royalties.

The new agreement sees the Vancouver-based biotech granting the Japanese pharma two more licenses for an upfront technology access fee of $18 million. It stands to receive up to $466.7 in clinical, regulatory and commercial milestones, with tiered royalties also up for grabs.

“Expanding our relationship with a leading global pharmaceutical partner like Daiichi Sankyo is extremely satisfying as it underscores the power, versatility and attractiveness of our technology platforms,” said Ali Tehrani, Ph.D., president and CEO of Zymeworks. “Having already used our platforms to discover one bispecific antibody, Daiichi Sankyo now has increased access to our technology to create additional therapeutic candidates. We are pleased to be working with a healthcare pioneer with a proven track record of over 100 years of innovation leading to major breakthroughs in patient care.”

The Azymetric technology works by doubling up on a drug’s potential target, offering a complementary approach to the Efect platform, a library of antibody Fc modifications that can be used to orchestrate an immune response: either turning it up or tamping it down.

Zymeworks has been on a dealmaking roll over the past few years. This includes an agreement with Janssen last November around six bispecific antibodies that saw it pick up $50 million up front, with another potential $282 million in development milestones and up to $1.12 billion in sales payments. Also in 2017, Zymeworks inked an R&D pact with The University of Victoria and BC Cancer Agency to develop engineered cytokine and cytokine receptor pairs.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).